Gsk (GSK) Net Cash Flow (2009 - 2026)
Gsk (GSK) recorded quarterly Net Cash Flow of $210.3 million in Q1 2026, up 152.36% quarter-over-quarter from -$401.7 million in Q4 2025, and down 83.55% on a YoY basis from $1.3 billion in Q1 2025.
Gsk (GSK) Net Cash Flow (2009 - 2026) Analysis & Trends
Gsk's Net Cash Flow history runs 18 years deep, the most recent figure standing at $210.3 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 83.55% year-over-year to $210.3 million; the TTM figure through Mar 2026 stood at -$191.4 million (down 108.53% YoY), while the FY2025 annual figure was -$233.4 million, down 130.48% from the prior year.
- Net Cash Flow was $210.3 million for Q1 2026 at Gsk, up from -$401.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $9.3 billion in Q1 2022 to a low of -$533.6 million in Q1 2023.
- Historically, Net Cash Flow has averaged $1.5 billion across 5 years, with a median of $307.8 million in 2023.
- Biggest YoY gain for Net Cash Flow was 1314.2% in 2025; the steepest drop was 141.56% in 2025.
- A 5-year view of Net Cash Flow shows it stood at $2.1 billion in 2022, then tumbled by 85.38% to $307.8 million in 2023, then soared by 213.99% to $966.5 million in 2024, then sank by 141.56% to -$401.7 million in 2025, then jumped by 152.36% to $210.3 million in 2026.
- The last three Net Cash Flow figures came in at $210.3 million (Q1 2026), -$401.7 million (Q4 2025), and $1.3 billion (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 210.32 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | -2.05 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 4.17 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -587.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 210.32 Mn |
| Mar 31, 2026 | 210.32 Mn |
| Dec 31, 2025 | -401.71 Mn |
| Dec 31, 2025 | -401.71 Mn |
| Mar 31, 2025 | 1.28 Bn |
| Mar 31, 2025 | 1.28 Bn |
| Dec 31, 2024 | 966.48 Mn |
| Dec 31, 2024 | 966.48 Mn |
| Mar 31, 2024 | -105.29 Mn |
| Mar 31, 2024 | -105.29 Mn |
| Dec 31, 2023 | 307.81 Mn |
| Dec 31, 2023 | 307.81 Mn |
| Mar 31, 2023 | -533.61 Mn |
| Mar 31, 2023 | -533.61 Mn |
| Dec 31, 2022 | 2.11 Bn |
| Dec 31, 2022 | 2.11 Bn |
| Mar 31, 2022 | 9.29 Bn |
| Mar 31, 2022 | 9.29 Bn |
| Dec 31, 2021 | 6.18 Bn |
| Dec 31, 2021 | 6.18 Bn |